Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

DIAGNOSTICA STAGO

Offers a complete system of hemostasis instrumentation and optimized reagent kits for research, as well as for routin... read more Featured Products: More products

Download Mobile App




Coagulation and Fibrinolysis Assessed in Splenic Injury Patients

By LabMedica International staff writers
Posted on 19 May 2021
The most frequently injured solid organ following blunt abdominal trauma is the spleen. More...
Splenectomy was a standard surgical procedure for splenic injury until the mid‐20th century. However, thrombotic and infectious complications following splenectomy were demonstrated by many studies.

Thrombocytosis, alterations of coagulation and fibrinolysis contribute to hypercoagulability and thromboembolism. Platelet (PLT) count, fibrinogen (FIB), D‐dimers (D‐D), fibrinogen/fibrin degradation products (FDP), antithrombin III (AT III) are key markers of coagulation and fibrinolytic activity. Prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT) are used for routine coagulation testing.

Emergency Medicine Specialist at the University of Science and Technology of China (Hefei, China) included in a study 38 blunt splenic injury (BSI). Splenic artery embolization (SAE) was performed if the splenic injury was classed as grade III or greater and had no requirement of immediate surgery.

Blood samples were collected in tubes containing EDTA for PLT count and Hb, hematocrit (Hct) determinations, which were determined using Sysmex XE‐5000 automated hematology analyzer (Sysmex, Kobe, Japan). Samples were collected in tubes containing 3.2% sodium citrate and then centrifuged at 2,000 rpm for 20 minutes to obtain plasma, which was used for determining coagulation and fibrinolysis parameters. FIB, D‐D, FDP, AT III, PT, APTT, and TT were measured on the STA‐R Evolution automated coagulation analyzer with identical commercial kit (Diagnostica Stago, Asnieres, France).

The medical team reported that the technical success rate of SAE and the splenic salvage rate were 100%. There was no mortality. Compared with pre‐SAE values, the levels of PLT, FIB, D‐D, and FDP increased significantly at three days and seven days after SAE. However, AT III, PT, APTT, TT, Hb, and Hct showed no statistically significant difference at one day, three days, and seven days after SAE.

The authors concluded that they had demonstrated that PLT significantly increased and activation of coagulation and fibrinolysis took place in BSI patients undergoing SAE. These alterations might have contributed to the increased risk of thrombotic complications, especially three days and seven days after SAE. Despite SAE as a critical treatment is used extensively in BSI patients and has increased the success rate of NOM, thromboembolism following SAE should be considered and thrombotic prophylaxis should be recommended. The study was published on May 6, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
University of Science and Technology of China
Sysmex
Diagnostica Stago



New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.